Novanta Earnings Call Highlights Growth and Margin Rebound

Novanta ((NOVT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Novanta’s latest earnings call struck a broadly upbeat tone, with management emphasizing accelerating growth, expanding profitability and powerful cash generation. Executives acknowledged near-term gross margin pressure from tariffs and freight, but framed these as temporary timing issues, with actions already underway to restore and expand margins later this year.

Revenue Growth and Upgraded Guidance

Novanta posted 10% year-over-year revenue growth in Q1, with 3% organic growth marking an important inflection from the prior quarter. Management responded by raising full-year GAAP revenue guidance to $1,040M–$1,055M, implying more than 7% reported growth and up to 6% organic growth, and they now expect Q2 organic growth between 6% and 8%.

Surging Bookings and Strengthening Backlog

Bookings jumped 37% year-over-year, driving a healthy book-to-bill ratio of 1.10 and signaling strong demand across the portfolio. All business units delivered double-digit bookings growth, and management highlighted a growing committed backlog that helps underpin confidence in the company’s outlook through 2026.

Improving Profitability Metrics

Adjusted EBITDA increased 14% year-over-year to $57M, lifting the margin by about 70 basis points to 22% despite cost headwinds. Adjusted diluted EPS climbed 9% to $0.81, and full-year guidance now calls for adjusted EBITDA of $245M–$250M and EPS of $3.50–$3.65, representing double-digit EBITDA growth and mid- to high-single-digit EPS growth.

Cash Flow Strength and Net Cash Position

Operating cash flow surged 63% year-over-year to $52M, translating into cash conversion above 200% of net income in the quarter. With $389M of cash, $249M of gross debt and a net cash position of $139M, the balance sheet remains very strong, allowing Novanta to repurchase about $18M of its own stock while retaining ample flexibility.

New Product Momentum and Design Wins

New product revenue grew roughly 50% year-over-year, pushing the Vitality Index to 27% of sales and signaling that recent R&D is translating into tangible revenue. Company-wide design wins rose nearly 30%, led by more than 70% new product growth in Automation and about 45% growth in new product sales in Medical Solutions.

Broad-Based Segment Performance

Medical Solutions revenue increased 15% year-over-year, with Advanced Surgery up 11% and Precision Medicine up 18%, helped by the Keonn acquisition. Robotics & Automation revenue rose 7% as bookings surged 50%, while Precision Manufacturing returned to 6% growth and delivered its fifth consecutive quarter of double-digit bookings growth.

Leveraging GenAI and Semiconductor Tailwinds

About 15% of Novanta’s revenue now ties to GenAI-related data centers and advanced semiconductor applications, and that slice grew roughly 20% year-over-year in Q1. Management expects this exposure to accelerate and noted the company’s participation in an AI systems inspection lab, highlighting its positioning in safety-focused, AI-driven robotics.

Operational Initiatives and Strategic Execution

Management is moving ahead with regional manufacturing consolidation, including two facility closures slated to complete in Q2, which are expected to lift gross margins in the second half. Executives also pointed to a deep pipeline of acquisition opportunities and reiterated a disciplined capital deployment approach to support long-term strategic priorities.

Gross Margin Pressure from Tariffs and Inflation

Adjusted gross margin came in at $118M, or 45.6%, down about 60 basis points year-over-year as tariffs, higher freight and material costs outpaced pricing actions. The Automation segment was notably affected, with management emphasizing that these cost pressures are timing-driven and should be mitigated as repricing and surcharges catch up.

Temporary EPS Headwind from Cost Spikes

The sudden cost inflation and tariff increases created a modest drag on earnings in the quarter, equating to roughly a $0.03 headwind to adjusted EPS. Management stressed that this impact is temporary and should abate as newly implemented surcharges and pricing adjustments flow through the income statement.

Pricing Lag and Repricing of Backlog

Rapid tariff changes and new freight surcharges created a mismatch between Novanta’s input costs and the prices locked into existing orders. In response, the company is actively repricing backlog and pushing through surcharges and price increases, but they expect the bulk of the financial benefit to show up in the second half of the year.

Regional Shipping Shifts and Sales Volatility

Reported U.S. sales declined year-over-year, but management attributed this to customers shifting factory production to locations such as Mexico and Costa Rica rather than weaker underlying demand. These production moves can cause regional volatility in reported revenue by geography even when global end-market demand remains healthy.

Operating Expense and Compensation Timing

For Q2, Novanta guided R&D plus SG&A to about $74M–$75M, or 28%–29% of sales, reflecting continued investment in innovation and commercial capabilities. Stock-based compensation, which totaled $10M in Q1 and includes a future one-time award, is also adding timing variability to operating expenses through the coming periods.

Execution Timing and Macro Risks

Several of Novanta’s key growth drivers, including advanced semiconductor tools and robotics and GenAI applications, are expected to ramp more meaningfully in the back half of the year and into 2027. Management nonetheless cautioned that macroeconomic, trade and geopolitical complexities could affect the precise timing of these ramps and the overall trajectory.

Guidance and Forward-Looking Outlook

For Q2, Novanta expects GAAP revenue of $259M–$264M, organic growth of 6%–8%, adjusted EBITDA of $58M–$62M and EPS of $0.81–$0.86, implying high-teens EBITDA growth and solid margin expansion. For the full year, the company reaffirmed revenue, EBITDA and EPS guidance, targets mid-single-digit organic growth, at least 100% cash conversion and a planned gross margin step-up in the second half as pricing actions and site closures begin to pay off.

Novanta’s earnings call painted a picture of a company balancing near-term cost noise with strong underlying demand and solid execution. With bookings surging, cash flow robust and exposure to structural growth themes like GenAI and semiconductors, management sounded confident that margin repair and accelerating growth in the back half can support continued value creation for shareholders.